文献速递血栓与止血

五种促血栓基因型与癌症对首次静脉血栓栓塞事件风险的联合效应

Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event.
PubMed 文献 · J Thromb Haemost · 2020-10-05

基于人群的病例-队列研究,纳入首次静脉血栓栓塞(VTE)病例1493例和亚队列13072人,评估5个单核苷酸多态性(SNP)风险评分与癌症状态对VTE风险的联合影响。中位随访12.3年,癌症患者232例发生VTE;无癌症者≥4个风险等位基因相比0-1个的HR为2.17(95%CI 1.79-2.62),癌症患者相应HR为1.93(95%CI 1.28-2.91);癌症合并≥4个风险等位基因者相比无癌症且0-1个风险等位基因者VTE风险高17倍(HR 17.1,95%CI 12.5-23.4)。

要点

  • 无癌症者≥4个风险等位基因相比0-1个的VTE风险HR为2.17(95%CI 1.79-2.62)。
  • 癌症患者≥4个风险等位基因相比0-1个的VTE风险HR为1.93(95%CI 1.28-2.91)。
  • 癌症合并≥4个风险等位基因者相比无癌症且0-1个风险等位基因者VTE风险HR为17.1(95%CI 12.5-23.4)。

核心结论

  • 在有和无癌症的受试者中,VTE风险随促血栓风险等位基因数量增加而升高,促血栓风险等位基因与癌症联合导致VTE风险高度升高。

研究设计与样本

  • 基于人群的病例-队列研究,病例为首次VTE患者(n=1493),亚队列为13072人,来自Tromsø研究(1994-2012)和Nord-Trøndelag健康研究(1995-2008)。
  • 对既往报道的5个SNP风险评分进行基因分型:ABO(rs8176719)、F5(rs6025)、F2(rs1799963)、FGG(rs2066865)和F11(rs2036914)。
  • 按癌症状态和5-SNP评分风险等位基因数(0-1、2-3和≥4个等位基因)估计VTE的风险比(HR)。

主要发现

  • 中位随访12.3年,1496人被诊断为癌症,其中232人发生VTE。
  • 无癌症受试者中,≥4个风险等位基因相比0-1个的VTE风险HR为2.17(95%CI 1.79-2.62)。
  • 癌症患者中,≥4个风险等位基因相比0-1个的VTE风险HR为1.93(95%CI 1.28-2.91)。
  • 癌症合并≥4个风险等位基因者相比无癌症且0-1个风险等位基因者,VTE风险HR为17.1(95%CI 12.5-23.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of combined prothrombotic genotypes in cancer-related venous thromboembolism (VTE) is scarcely studied. We aimed to investigate the impact of a 5-single nucleotide polymorphism (SNP) score on the risk of VTE in patients with and without cancer using a population-based case-cohort. METHODS: Cases with a first VTE (n = 1493) and a subcohort (n = 13 072) were derived from the Tromsø Study (1994-2012) and the Nord-Trøndelag Health Study (1995-2008). Five SNPs previously reported as a risk score were genotyped: ABO (rs8176719), F5 (rs6025), F2 (rs1799963), FGG (rs2066865), and F11 (rs2036914). Hazard ratios (HRs) for VTE were estimated according to cancer status and the number of risk alleles in the 5-SNP score (0-1, 2-3, and ≥4 alleles). RESULTS: During a median follow-up of 12.3 years, 1496 individuals were diagnosed with cancer, of whom 232 experienced VTE. The VTE risk increased with the number of risk alleles in the 5-SNP score among subjects without and with cancer. In cancer-free subjects, the HR was 2.17 (95% confidence interval [CI] 1.79-2.62) for ≥4 versus 0-1 risk alleles. In cancer patients, the corresponding HR was 1.93 (95% CI 1.28-2.91). The combination of cancer and ≥4 risk alleles yielded a 17-fold (HR 17.1, 95% CI 12.5-23.4) higher risk of VTE compared with cancer-free subjects with 0-1 risk alleles. CONCLUSION: The risk of VTE increases with the number of prothrombotic risk alleles in subjects with and without cancer, and the combination of prothrombotic risk alleles and cancer leads to a highly elevated risk of VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Skille H, Paulsen B, Hveem K, et al. Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. J Thromb Haemost. 2020. PMID: 32671915. doi:10.1111/jth.15011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。